BioCentury
ARTICLE | Data Byte

With $125M goal, Structure’s IPO would be among NASDAQ’s largest in a year

Cross-border company aiming for offering that would rank fifth among biotechs listing on NASDAQ in past 12 months

January 30, 2023 10:22 PM UTC

If Structure’s IPO is able to meet the company’s financial expectations, the offering would be the fifth-largest NASDAQ listing by a biotech in the past 12 months.

Structure Therapeutics Inc., a GPCR-focused company headquartered in the San Francisco Bay Area with some operations in China, disclosed in a regulatory filing that it will aim to sell nearly 9 million ADSs at $13-$15 in a NASDAQ offering, its first on any exchange. If it prices at the $14 midpoint, it would raise $125.3 million at a postmoney valuation of almost $500 million...

Get Unlimited Access
Continue reading with a free trial.
Or Purchase This Article